{"id":872785,"date":"2025-08-07T11:49:58","date_gmt":"2025-08-07T15:49:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\/"},"modified":"2025-08-07T11:49:58","modified_gmt":"2025-08-07T15:49:58","slug":"attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\/","title":{"rendered":"ATTENTION NASDAQ: SPPI INVESTORS: Contact Berger Montague About a Spectrum Pharmaceuticals Class Action Lawsuit"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">PHILADELPHIA, Aug.  07, 2025  (GLOBE NEWSWIRE) &#8212; National plaintiffs\u2019 law firm <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GkQxTcmK_zzwWVzs4RJR4niUz5QxpTsAwUYGkUf-U7YaqgTnDUHmTCMv6RkohITWVYVb5haQbBB0o1mtxqFKzqxxO8JztXy7xspitNcXq88=\" rel=\"nofollow\" target=\"_blank\"><u>Berger Montague PC<\/u><\/a> is investigating securities fraud claims against\u00a0<strong>Spectrum Pharmaceuticals, Inc. <\/strong>(<strong>NASDAQ: SPPI) <\/strong>(\u201cSpectrum\u201d or the \u201cCompany\u201d) on behalf of investors who purchased or otherwise acquired common shares of Spectrum between\u00a0<strong>March 17, 2022 through September 22, 2022 <\/strong>(the \u201cClass Period\u201d).<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>Investor Deadline:<\/em><br \/>\n        <\/strong><br \/>\n        <em> Investors who purchased or acquired <\/em><br \/>\n        <strong><br \/>\n          <em>Spectrum<\/em><br \/>\n        <\/strong><br \/>\n        <em> securities during the Class Period may, no later than <\/em><br \/>\n        <strong><br \/>\n          <em>September 24, 2025<\/em><br \/>\n        <\/strong><br \/>\n        <em>, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,<\/em><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vYg4f7Nbb4iHBTD9zMs2Rc8EdQ9DoPtb_GA2gUwwGLA6R24WesCN4_uqXQwRWKSO4DI3P0heZ9CBg0z8V9fGY597hFFOdBqeck_cveqGQwzJi-olAcHDg9-kaShM8cWX\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <u>CLICK HERE<\/u><br \/>\n          <\/strong><br \/>\n        <\/a><br \/>\n        <strong>.<\/strong>\n      <\/p>\n<p>Spectrum is a biopharmaceutical company focused on oncology treatments.<\/p>\n<p>The class action lawsuit alleges that Spectrum made false or misleading statements to investors regarding its Pinnacle Study, a clinical trial involving poziotinib, a drug intended to treat certain lung cancer patients.<\/p>\n<p>Spectrum shares were delisted following the Company\u2019s merger with Assertio Holdings, Inc. (NASDAQ: ASRT).<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>If you are a Spectrum investor and would like to learn more about this action, <\/em><br \/>\n        <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vYg4f7Nbb4iHBTD9zMs2RbqieJOBFw5OjpRp9wiSUJDuOBy463eMa76XNLqIQn_bHyJffNPeRB4Zp2yzN3dl0am0rhU-CrlB6wf4mRAjOhG-iyYFkHrJUpvnbXLbb91Y\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <em><br \/>\n              <u>CLICK HERE<\/u><br \/>\n            <\/em><br \/>\n          <\/strong><br \/>\n        <\/a><br \/>\n        <strong><br \/>\n          <em>or please contact Berger Montague: Andrew Abramowitz at <\/em><br \/>\n        <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7LBSCQNNyiMAzFpSxuc3u34bIUaXSZAFEWqo8j0_Srj9sD7dk38IC4YwBzthd31JOQqxvSwLym3ZvnFwFCVYCMKUaqLgsOjU9ThOrkF-vKCZEdkCMdTKch66ffRRWLXh\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <em><br \/>\n              <u>aabramowitz@bergermontague.com<\/u><br \/>\n            <\/em><br \/>\n          <\/strong><br \/>\n        <\/a><br \/>\n        <strong><br \/>\n          <em> or (215) 875-3015, or Caitlin Adorni at <\/em><br \/>\n        <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hYmfPWBFQhR1E_MioxTwrlX-5isexOIVCwHGF6RkaDObhomBuwnQhRoSfWHF2cTaiqOzCvzOhNcDwlhZ1Wb6tPu6Tnje3IUF5CsOXtvddyG1biSlFQuknz2-LU09H81D\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <em><br \/>\n              <u>cadorni@bergermontague.com<\/u><br \/>\n            <\/em><br \/>\n          <\/strong><br \/>\n        <\/a><br \/>\n        <strong><br \/>\n          <em> or (267)764-4865.<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>About Berger Montague<\/strong><br \/>\n        <br \/>Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto has been a pioneer in <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GHeuw9557_GoEyaxk9qbrBahZnmzChl473iD9GtVVwZZVyaXU6WwpMwF2Gr1zTlqW13PEJtP7Z9SFmzxKU8S0DJmPH1BDFhqDgK_AhCChB-LKc2UZVISDfQ7la_J2Fy47HuJ9-VCyKmU0cGQuW1UEA==\" rel=\"nofollow\" target=\"_blank\"><u>securities class action litigation<\/u><\/a> since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.<\/p>\n<p align=\"justify\">\n        <strong>For more information or to discuss your rights, please contact:<\/strong><br \/>\n        <br \/>Andrew Abramowitz, Senior Counsel<br \/>Berger Montague<br \/>(215) 875-3015<br \/>aabramowitz@bergermontague.com<\/p>\n<p align=\"justify\">Caitlin Adorni<br \/>Berger Montague<br \/>(267) 764-4865<br \/>cadorni@bergermontague.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwODE4MSM3MDg2NzE0IzIwODI5NjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NzY5YzRhZDItMDU4Yy00YjU2LWIzNDctYWM5YzFjZjM2NjQ0LTEwOTQ1MzMtMjAyNS0wOC0wNy1lbg==\/tiny\/Berger-Montague.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PHILADELPHIA, Aug. 07, 2025 (GLOBE NEWSWIRE) &#8212; National plaintiffs\u2019 law firm Berger Montague PC is investigating securities fraud claims against\u00a0Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) (\u201cSpectrum\u201d or the \u201cCompany\u201d) on behalf of investors who purchased or otherwise acquired common shares of Spectrum between\u00a0March 17, 2022 through September 22, 2022 (the \u201cClass Period\u201d). Investor Deadline: Investors who purchased or acquired Spectrum securities during the Class Period may, no later than September 24, 2025 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE . Spectrum is a biopharmaceutical company focused on oncology treatments. The class action lawsuit alleges that Spectrum made false or misleading statements to investors regarding its Pinnacle Study, a clinical &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ATTENTION NASDAQ: SPPI INVESTORS: Contact Berger Montague About a Spectrum Pharmaceuticals Class Action Lawsuit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-872785","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ATTENTION NASDAQ: SPPI INVESTORS: Contact Berger Montague About a Spectrum Pharmaceuticals Class Action Lawsuit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ATTENTION NASDAQ: SPPI INVESTORS: Contact Berger Montague About a Spectrum Pharmaceuticals Class Action Lawsuit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA, Aug. 07, 2025 (GLOBE NEWSWIRE) &#8212; National plaintiffs\u2019 law firm Berger Montague PC is investigating securities fraud claims against\u00a0Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) (\u201cSpectrum\u201d or the \u201cCompany\u201d) on behalf of investors who purchased or otherwise acquired common shares of Spectrum between\u00a0March 17, 2022 through September 22, 2022 (the \u201cClass Period\u201d). Investor Deadline: Investors who purchased or acquired Spectrum securities during the Class Period may, no later than September 24, 2025 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE . Spectrum is a biopharmaceutical company focused on oncology treatments. The class action lawsuit alleges that Spectrum made false or misleading statements to investors regarding its Pinnacle Study, a clinical &hellip; Continue reading &quot;ATTENTION NASDAQ: SPPI INVESTORS: Contact Berger Montague About a Spectrum Pharmaceuticals Class Action Lawsuit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-07T15:49:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwODE4MSM3MDg2NzE0IzIwODI5NjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ATTENTION NASDAQ: SPPI INVESTORS: Contact Berger Montague About a Spectrum Pharmaceuticals Class Action Lawsuit\",\"datePublished\":\"2025-08-07T15:49:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\\\/\"},\"wordCount\":277,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwODE4MSM3MDg2NzE0IzIwODI5NjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\\\/\",\"name\":\"ATTENTION NASDAQ: SPPI INVESTORS: Contact Berger Montague About a Spectrum Pharmaceuticals Class Action Lawsuit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwODE4MSM3MDg2NzE0IzIwODI5NjI=\",\"datePublished\":\"2025-08-07T15:49:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwODE4MSM3MDg2NzE0IzIwODI5NjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwODE4MSM3MDg2NzE0IzIwODI5NjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ATTENTION NASDAQ: SPPI INVESTORS: Contact Berger Montague About a Spectrum Pharmaceuticals Class Action Lawsuit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ATTENTION NASDAQ: SPPI INVESTORS: Contact Berger Montague About a Spectrum Pharmaceuticals Class Action Lawsuit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\/","og_locale":"en_US","og_type":"article","og_title":"ATTENTION NASDAQ: SPPI INVESTORS: Contact Berger Montague About a Spectrum Pharmaceuticals Class Action Lawsuit - Market Newsdesk","og_description":"PHILADELPHIA, Aug. 07, 2025 (GLOBE NEWSWIRE) &#8212; National plaintiffs\u2019 law firm Berger Montague PC is investigating securities fraud claims against\u00a0Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) (\u201cSpectrum\u201d or the \u201cCompany\u201d) on behalf of investors who purchased or otherwise acquired common shares of Spectrum between\u00a0March 17, 2022 through September 22, 2022 (the \u201cClass Period\u201d). Investor Deadline: Investors who purchased or acquired Spectrum securities during the Class Period may, no later than September 24, 2025 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE . Spectrum is a biopharmaceutical company focused on oncology treatments. The class action lawsuit alleges that Spectrum made false or misleading statements to investors regarding its Pinnacle Study, a clinical &hellip; Continue reading \"ATTENTION NASDAQ: SPPI INVESTORS: Contact Berger Montague About a Spectrum Pharmaceuticals Class Action Lawsuit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-07T15:49:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwODE4MSM3MDg2NzE0IzIwODI5NjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ATTENTION NASDAQ: SPPI INVESTORS: Contact Berger Montague About a Spectrum Pharmaceuticals Class Action Lawsuit","datePublished":"2025-08-07T15:49:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\/"},"wordCount":277,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwODE4MSM3MDg2NzE0IzIwODI5NjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\/","name":"ATTENTION NASDAQ: SPPI INVESTORS: Contact Berger Montague About a Spectrum Pharmaceuticals Class Action Lawsuit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwODE4MSM3MDg2NzE0IzIwODI5NjI=","datePublished":"2025-08-07T15:49:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwODE4MSM3MDg2NzE0IzIwODI5NjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwODE4MSM3MDg2NzE0IzIwODI5NjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attention-nasdaq-sppi-investors-contact-berger-montague-about-a-spectrum-pharmaceuticals-class-action-lawsuit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ATTENTION NASDAQ: SPPI INVESTORS: Contact Berger Montague About a Spectrum Pharmaceuticals Class Action Lawsuit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/872785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=872785"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/872785\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=872785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=872785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=872785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}